Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 32 clinical trials
Dasatinib Holiday for Improved Tolerability

Treatment optimization for patients with chronic myeloid leukemia (CML) with treatment nave disease (1st line) and patients with resistance or intolerance against alternative Abl-Kinase Inhibitors (2nd line) (DasaHIT Trial (Dasatinib Holiday for Improved Tolerability))

leukemia
imatinib
dasatinib
nilotinib
ponatinib
  • 11 views
  • 05 Feb, 2021
  • 80 locations
Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase

This study will investigate the efficacy and tolerability of a short (6 months) high dose therapy followed by a standard dose compared to a continuous treatment with a standard dose of imatinib (Glivec®) in pretreated Philadelphia chromosome- positive (Ph+)/BCR-ABL+ CML patients in chronic phase.

leukemia
imatinib
interferon
philadelphia chromosome
gleevec
  • 11 views
  • 07 Nov, 2020
  • 1 location
The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm

This trial aimed to investigate the therapeutic efficacy of ruxolitinib in combination with cytotoxic chemotherapy for post-myeloproliferative neoplasm secondary acute myeloid leukemia.

  • 1 views
  • 24 Jan, 2021
  • 2 locations
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias or Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 to < 18 years with advanced leukemias, lymphomas, and solid tumors.

chronic myeloid leukemia
leukemia
alopecia
KIT
myeloid leukemia
  • 23 views
  • 26 Jan, 2021
  • 32 locations
Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

This phase II trial studies how well decitabine with ruxolitinib or fedratinib works before hematopoietic stem cell transplant in treating patients with accelerated/blast phase

secondary myelofibrosis
leukapheresis
myelodysplastic/myeloproliferative neoplasms
hemolysis
blast cells
  • 7 views
  • 26 Feb, 2021
  • 1 location
Decitabine Venetoclax and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

myeloid blast phase or accelerated phase chronic myelogenous leukemia.

leukemia
myeloid leukemia
remission
hemolysis
blast cells
  • 0 views
  • 27 Apr, 2021
Cladribine Idarubicin Cytarabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia High-Risk Myelodysplastic Syndrome or Blastic Phase Chronic Myeloid Leukemia

This phase II trial studies how well cladribine, idarubicin, cytarabine, and venetoclax work in patients with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blastic phase chronic

leukemia
cancer
myeloid leukemia
refractory acute myeloid leukemia (aml)
cladribine
  • 42 views
  • 25 Jan, 2021
  • 1 location
Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia"

This is a Phase 1-2, multicenter, international, single-arm, open-label study designed to identify a recommended dose of bosutinib administered orally once daily in pediatric patients with newly diagnosed chronic phase Ph+ CML (ND CML) and pediatric patients with Ph+CML who have received at least one prior TKI therapy (R/I CML), …

leukemia
myeloid leukemia
ejection fraction
growth factor
absolute neutrophil count
  • 0 views
  • 13 Jun, 2021
  • 30 locations
Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

The presence of IDH mutation is associated with worse survival in patients with myelofibrosis. Moreover IDH mutations are among the most frequently encountered events in MPNs that have progressed to acute myeloid leukemia. Ruxolitinib, a JAK1/2 inhibitor, and enasidenib an IDH2 inhibitor are effective and tolerable treatments for patients with …

  • 0 views
  • 30 May, 2021
  • 11 locations
PONAZA : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS

This project is strategy aiming to improve the survival of patients with chronic myelogenous leukemia in advanced phase and myeloid blast crisis. The basis of this strategy is to add the

  • 1 views
  • 25 Jan, 2021
  • 26 locations